| scholarly article | Q13442814 |
| P2093 | author name string | Subrata Sen | |
| Hiroshi Katayama | |||
| P2860 | cites work | Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. | Q46847084 |
| Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. | Q51843173 | ||
| INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow. | Q52541041 | ||
| Aurora kinase-A regulates kinetochore/chromatin associated microtubule assembly in human cells. | Q53455909 | ||
| The N-terminal domain of the Aurora-A Phe-31 variant encodes an E3 ubiquitin ligase and mediates ubiquitination of IkappaBalpha. | Q53591938 | ||
| Validating Aurora B as an anti-cancer drug target. | Q53605080 | ||
| A novel mechanism for activation of the protein kinase Aurora A | Q73280786 | ||
| MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation | Q80312874 | ||
| AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo | Q80313902 | ||
| Divide and conquer: new generation of drugs targets mitosis | Q81852812 | ||
| Aurora kinase inhibitors in preclinical and clinical testing | Q83589206 | ||
| Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together | Q24298466 | ||
| Structural basis of Aurora-A activation by TPX2 at the mitotic spindle | Q24298490 | ||
| Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma | Q24311457 | ||
| Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery | Q24311665 | ||
| A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2 | Q24321340 | ||
| The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint | Q24675117 | ||
| Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency | Q24681743 | ||
| Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358 | Q27647889 | ||
| Molecular basis of drug resistance in aurora kinases | Q27650856 | ||
| Discovery of a potent and selective aurora kinase inhibitor | Q27651407 | ||
| Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity | Q27653420 | ||
| Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors | Q27658951 | ||
| Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry | Q28115829 | ||
| Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores | Q28201606 | ||
| BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition | Q28247388 | ||
| Cell cycle kinases as therapeutic targets for cancer | Q28250447 | ||
| A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers | Q28272347 | ||
| Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation | Q28285317 | ||
| Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2 | Q28307811 | ||
| Chromosomal passengers: conducting cell division | Q29620468 | ||
| Growth and tumor suppressor NORE1A is a regulatory node between Ras signaling and microtubule nucleation | Q30432256 | ||
| MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy | Q30479689 | ||
| A role for IkappaB kinase 2 in bipolar spindle assembly | Q30480263 | ||
| A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function | Q30487453 | ||
| Allosteric inhibitors of Bcr-abl-dependent cell proliferation | Q33231742 | ||
| Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways | Q33494220 | ||
| AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo | Q39861028 | ||
| The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo | Q39874735 | ||
| Short and long-term tumor cell responses to Aurora kinase inhibitors | Q39881304 | ||
| The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents | Q39883162 | ||
| The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | Q39893220 | ||
| Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies | Q39989501 | ||
| Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells | Q40009243 | ||
| Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. | Q40014063 | ||
| Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia | Q40030607 | ||
| PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. | Q40033870 | ||
| The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. | Q40036249 | ||
| AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis | Q40118416 | ||
| Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase | Q40156540 | ||
| Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha | Q40169627 | ||
| 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. | Q40204675 | ||
| Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents | Q40206974 | ||
| The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function | Q40248512 | ||
| Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition | Q40435650 | ||
| Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. | Q40473985 | ||
| Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. | Q40506957 | ||
| Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors | Q40509516 | ||
| Overexpression and amplification of Aurora-A in hepatocellular carcinoma | Q40574136 | ||
| Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks | Q43096508 | ||
| The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells | Q43160220 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors | Q43273405 | ||
| SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo | Q43299750 | ||
| BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice | Q44196757 | ||
| Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis | Q44353700 | ||
| Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. | Q45345467 | ||
| GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. | Q45945470 | ||
| Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. | Q46002468 | ||
| Pharmacologic abrogation of the mitotic spindle checkpoint by an indolocarbazole discovered by cellular screening efficiently kills cancer cells | Q46051196 | ||
| Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. | Q46089532 | ||
| Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia | Q46225442 | ||
| Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. | Q46462162 | ||
| A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors | Q33676809 | ||
| Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer | Q33732173 | ||
| Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). | Q33867046 | ||
| Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases | Q33906140 | ||
| Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment | Q34268535 | ||
| VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo | Q34300737 | ||
| Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells | Q34544793 | ||
| Roles of Aurora kinases in mitosis and tumorigenesis. | Q34574449 | ||
| Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma. | Q34580499 | ||
| Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia | Q34622576 | ||
| Aurora kinases as anticancer drug targets | Q34762466 | ||
| Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase | Q35676802 | ||
| Aurora-kinase inhibitors as anticancer agents | Q35968406 | ||
| "Oncogenic shock": explaining oncogene addiction through differential signal attenuation | Q36542437 | ||
| A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy | Q36720750 | ||
| Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. | Q36876794 | ||
| Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia | Q36915927 | ||
| Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells | Q36984707 | ||
| Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells | Q37038388 | ||
| The aurora kinase A regulates GSK-3beta in gastric cancer cells | Q37096754 | ||
| The Aurora kinase family in cell division and cancer. | Q37228956 | ||
| Molecular distinctions between Aurora A and B: a single residue change transforms Aurora A into correctly localized and functional Aurora B | Q37285662 | ||
| Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model | Q37328115 | ||
| Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. | Q37398815 | ||
| Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins | Q37616620 | ||
| Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma | Q37639189 | ||
| Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma | Q37663791 | ||
| Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. | Q37666259 | ||
| Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. | Q39732167 | ||
| MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo | Q39733225 | ||
| Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. | Q39735770 | ||
| p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells | Q39762903 | ||
| Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA | Q39777040 | ||
| Analysis of Aurora B kinase in non-Hodgkin lymphoma | Q39788234 | ||
| The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe | Q39799336 | ||
| Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. | Q39851931 | ||
| The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model | Q39860026 | ||
| P433 | issue | 10-12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 829-839 | |
| P577 | publication date | 2010-09-20 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Aurora kinase inhibitors as anticancer molecules | |
| P478 | volume | 1799 |
| Q39010396 | A comparative study of the aneugenic and polyploidy-inducing effects of fisetin and two model Aurora kinase inhibitors |
| Q41880506 | A framework for image-based classification of mitotic cells in asynchronous populations |
| Q37976467 | A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets |
| Q84567819 | A new analysis of testicular proteins through integrative bioinformatics |
| Q38944768 | A new small-molecule Aurora B inhibitor shows antitumor activity in human cancer cell lines. |
| Q35996051 | A novel role for TPX2 as a scaffold and co-activator protein of the Chromosomal Passenger Complex |
| Q42544809 | A role for p38 in transcriptional elongation of p21 (CIP1) in response to Aurora B inhibition |
| Q98772061 | AURKA Increase the Chemosensitivity of Colon Cancer Cells to Oxaliplatin by Inhibiting the TP53-Mediated DNA Damage Response Genes |
| Q28386389 | Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells |
| Q36359519 | Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases |
| Q37593293 | Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior |
| Q37279302 | Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis |
| Q35356178 | Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer |
| Q33579079 | Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells |
| Q27677506 | Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules |
| Q27853047 | Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis |
| Q38957015 | Aurora-A enhances malignant development of esophageal squamous cell carcinoma (ESCC) by phosphorylating β-catenin |
| Q54144282 | Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration. |
| Q38835387 | Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition. |
| Q53075287 | CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. |
| Q38935027 | Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic |
| Q27022355 | Current and future trials of targeted therapies in cutaneous melanoma |
| Q28388312 | DNA damage response genes and the development of cancer metastasis |
| Q56889888 | Dynamics of human protein kinase Aurora A linked to drug selectivity |
| Q91990840 | Effect of CCT137690 on long non-coding RNA expression profiles in MCF-7 and MDA-MB-231 cell lines |
| Q47119995 | Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer |
| Q45096619 | Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern |
| Q36367628 | Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis |
| Q34055936 | Functional kinomics identifies candidate therapeutic targets in head and neck cancer |
| Q38400379 | Gene expression of Aurora kinases in prostate cancer and nodular hyperplasia tissues |
| Q91999877 | Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition |
| Q42787685 | Germline deletion of FAK-related non-kinase delays post-natal cardiomyocyte mitotic arrest |
| Q35889822 | Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation |
| Q24304083 | Identification of Ski as a target for Aurora A kinase |
| Q39000130 | Induction of p21CIP1 protein and cell cycle arrest after inhibition of Aurora B kinase is attributed to aneuploidy and reactive oxygen species. |
| Q39429784 | Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. |
| Q36108892 | Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy. |
| Q39052359 | Involvement of caspase-2 activation in aurora kinase inhibitor-induced cell death in axin-expressing L929 cells |
| Q35073744 | Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism |
| Q53171098 | MARCKS actin-binding capacity mediates actin filament assembly during mitosis in human hepatic stellate cells. |
| Q35816817 | Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family |
| Q36763730 | Molecular evidence of cryptotanshinone for treatment and prevention of human cancer |
| Q37259845 | Multi-omics approach to infer cancer therapeutic targets on chromosome 20q across tumor types. |
| Q47547178 | Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer |
| Q89528234 | New landscapes and horizons in hepatocellular carcinoma therapy |
| Q64082641 | New type of interaction between the SARAH domain of the tumour suppressor RASSF1A and its mitotic kinase Aurora A |
| Q28261162 | PIM1 kinase as a target for cancer therapy |
| Q38679311 | Personalized Therapy of Small Cell Lung Cancer |
| Q47251589 | Phthalazinone Pyrazole Enhances the Hepatic Functions of Human Embryonic Stem Cell-Derived Hepatocyte-Like Cells via Suppression of the Epithelial-Mesenchymal Transition. |
| Q46827793 | Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships |
| Q37323073 | Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma |
| Q54484484 | QSAR studies on imidazopyrazine derivatives as Aurora A kinase inhibitors. |
| Q39449209 | RalA is overactivated in medulloblastoma |
| Q37687413 | Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases |
| Q40922875 | Regulation of AURKC expression by CpG island methylation in human cancer cells. |
| Q39188213 | S39, a novel Aurora B kinase inhibitor, shows potent antineoplastic activity in human Hela cervical cancer cell line |
| Q41717003 | Specificity rendering 'hot-spots' for aurora kinase inhibitor design: the role of non-covalent interactions and conformational transitions |
| Q38671036 | Targeting mitotic pathways for endocrine-related cancer therapeutics |
| Q39327085 | Tetraploidization increases sensitivity to Aurora B kinase inhibition. |
| Q39178333 | The impaired viability of prostate cancer cell lines by the recombinant plant kallikrein inhibitor. |
| Q35642841 | The proliferation rate paradox in antimitotic chemotherapy |
| Q33782364 | The σ2 receptor: a novel protein for the imaging and treatment of cancer |
| Q52812759 | Theoretical Studies on Azaindoles as Human Aurora B Kinase Inhibitors: Docking, Pharmacophore and ADMET Studies. |
| Q36763844 | Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma |
| Q38298911 | Transcriptome analysis of the cancer/testis genes, DAZ1, AURKC, and TEX101, in breast tumors and six breast cancer cell lines |
| Q55312776 | Universal response in the RKO colon cancer cell line to distinct antimitotic therapies. |
Search more.